MedChunk
Medically reviewed

AMH Levels After Menopause: Causes and What It Means

AMH usually becomes very low or undetectable after menopause. Learn what a detectable or high result may mean, why it happens, and when follow-up is needed.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 12 min read

AMH (anti-Müllerian hormone) levels normally become very low or undetectable after menopause because the ovaries have very few developing follicles left. A detectable or unexpectedly high AMH level after menopause may need further evaluation, depending on the result and medical history. In some cases, it may be related to differences in laboratory testing or an ovarian condition, including a rare granulosa cell tumor.

Why Do AMH Levels Become Low After Menopause?

AMH is a hormone made by granulosa cells, which surround and support developing eggs inside the ovaries. Its level in the blood reflects the number of small, growing follicles in the ovaries. These follicles represent part of the ovarian reserve, meaning the remaining supply of eggs that may develop.

As a woman gets older, the number of ovarian follicles gradually decreases. The ovaries therefore produce less AMH over time. By menopause, ovarian follicle activity has declined substantially, so AMH levels are generally very low or below the detection limit of the test.

According to MedlinePlus, AMH levels decrease as the egg supply shrinks and drop to very low levels at menopause. This is a normal part of reproductive aging rather than a disease.

Menopause also involves changes in other reproductive hormones, including estrogen and follicle-stimulating hormone (FSH). These hormones have different functions from AMH. Therefore, an AMH result should not be interpreted as a direct measurement of estrogen levels or menopausal symptoms.

What Is a Normal AMH Level After Menopause?

After natural menopause, AMH is generally expected to be very low or undetectable. However, there is no single numerical cutoff that applies to every postmenopausal woman across all laboratory testing methods.

AMH results are commonly reported in units such as nanograms per milliliter (ng/mL) or picomoles per liter (pmol/L). The laboratory's testing method and reference information are important when interpreting the result.

There are several reasons why a universal numerical range is difficult to establish:

  • Different testing methods: Laboratories use different AMH measurement systems, which may produce different numerical results from the same sample.
  • Detection limits: Some tests can measure extremely small amounts of AMH, while others may report results below their detection limit as undetectable.
  • Reference ranges: Laboratory reference information may differ depending on the testing platform and population studied.

A review published in Fertility and Sterility Reports, available through the National Library of Medicine, describes differences between AMH testing platforms and explains why results from different laboratories are not always directly comparable.

For this reason, a small detectable AMH value should not automatically be considered abnormal. It is important to consider the actual result, the laboratory's reference information, and the reason the test was requested.

What Does a Detectable AMH Level After Menopause Mean?

A detectable AMH result means that the laboratory has measured some amount of the hormone in the blood. This finding is different from a high AMH level and does not automatically indicate an underlying health problem.

In a postmenopausal woman, the meaning of a detectable result depends on several factors, including whether the result is only slightly above the detection limit, whether previous results are available, and whether there is a history of ovarian disease.

Possible explanations include:

  • Differences in laboratory testing: A result may be measurable with one testing platform but fall below the detection limit of another. This can create apparent differences between results.
  • Remaining ovarian tissue or follicular activity: AMH is produced by developing ovarian follicles. A detectable result may need to be considered alongside the person's ovarian history and clinical circumstances.
  • Granulosa cell tumors: Certain ovarian tumors develop from granulosa cells, which normally produce AMH. Some of these tumors can produce measurable or increased amounts of the hormone.
  • Previous ovarian tumor history: In women previously treated for certain ovarian tumors, AMH may be measured as part of follow-up when it was elevated at the original diagnosis.

The presence of measurable AMH alone cannot identify which explanation applies. A clinician needs to interpret the result alongside other relevant findings.

What Can Cause High AMH Levels After Menopause?

A clearly elevated AMH level is not the usual finding after natural menopause. When a result is higher than expected, healthcare professionals may consider laboratory factors and certain ovarian conditions.

Granulosa Cell Tumors of the Ovary

One important condition associated with increased AMH is a granulosa cell tumor. This is an uncommon type of ovarian tumor that develops from granulosa cells. These cells normally produce AMH during follicle development.

Adult-type granulosa cell tumors occur most commonly in adult women and can develop during the perimenopausal or postmenopausal years. Some tumors produce AMH, making the hormone useful as a tumor marker in selected patients.

According to the medical review Granulosa Theca Cell Tumors of the Ovary, available through the National Library of Medicine, combining AMH measurements with inhibin B testing can improve the detection of recurrent granulosa cell tumors.

These tumors may be associated with symptoms such as:

  • Persistent abdominal swelling or distension
  • Pelvic discomfort or pain
  • A feeling of pressure in the lower abdomen
  • Signs of excess estrogen production, which may affect the uterine lining

These symptoms do not establish the presence of a tumor. Many other conditions can cause similar experiences. However, persistent or unusual pelvic symptoms, particularly after menopause, deserve medical evaluation.

Importantly, an elevated AMH result by itself does not diagnose ovarian cancer. Further assessment is needed when the medical history, examination, or other findings raise a concern.

Differences Between AMH Laboratory Assays

Not every unexpected AMH result reflects a change in ovarian activity. Different laboratories use different methods to measure AMH, and the numerical results may not be interchangeable.

For example, a woman might receive an undetectable result from one laboratory and a small measurable result from another. This difference does not necessarily mean that her ovarian hormone production has increased.

When results appear inconsistent, healthcare professionals may review the testing method, laboratory reference information, and previous measurements. Comparing results obtained using the same testing method may provide a more useful picture over time.

Does Detectable AMH Mean Menopause Has Not Occurred?

No. Detectable AMH does not automatically mean that menopause has not occurred or that normal reproductive function has returned.

Menopause is generally identified through menstrual history and clinical assessment. In women older than 45 with typical menopausal changes, hormone testing is usually unnecessary to establish the diagnosis.

The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause explains that AMH is not yet clearly useful for diagnosing menopause. Although AMH decreases during the later reproductive years, age has a greater influence on its levels than reproductive stage.

A detectable result therefore needs to be interpreted separately from the clinical determination of menopause. Other medical information is more important when establishing whether a woman has reached this stage of life.

Can AMH Levels Increase Again After Menopause?

AMH generally decreases as ovarian follicles become depleted. A substantial increase after menopause is not considered a normal reversal of ovarian aging.

If a later blood test shows a higher value than an earlier one, several questions need consideration:

  • Were both tests performed by the same laboratory?
  • Did the laboratory use the same measurement method?
  • Was the earlier result below the test's detection limit?
  • Is there a history of an ovarian condition or previous ovarian surgery?
  • Was AMH being monitored as part of treatment or follow-up for an ovarian tumor?

A difference between two results does not necessarily represent a biological increase. Laboratory variation and the sensitivity of the testing method can affect how small amounts of AMH are reported.

For women with a history of granulosa cell tumors, however, a confirmed rise may have a different clinical meaning and should be reviewed by the treating specialist.

Is AMH Used to Monitor Ovarian Tumors After Menopause?

Yes. In selected women with a history of granulosa cell tumors, AMH can be useful for monitoring the condition after treatment.

These tumors may produce AMH, and the hormone can sometimes help clinicians assess whether the disease has returned or persisted. Its usefulness depends partly on whether AMH was elevated when the tumor was first diagnosed.

A 2025 review, Cancer of the ovary, fallopian tube, and peritoneum: 2025 update, published in the International Journal of Gynecology and Obstetrics, describes AMH and inhibin B as useful follow-up markers in patients whose granulosa cell tumors had elevated levels of these markers at diagnosis.

This is an important distinction: measuring AMH for follow-up in someone with an established tumor is different from using AMH as a routine screening test for ovarian cancer in otherwise healthy postmenopausal women.

How Are Unexpected AMH Results Evaluated After Menopause?

When an AMH result is detectable or higher than expected, the next steps depend on the degree of elevation, medical history, and any associated symptoms.

A healthcare professional may consider the following information:

  • Previous AMH results: Earlier measurements can help determine whether the current result is new, persistent, or part of an established monitoring pattern.
  • Laboratory information: The testing method, units, reference range, and detection limit help clarify the meaning of the result.
  • Ovarian and surgical history: Previous ovarian conditions, operations, and treatment for ovarian tumors may affect how the result is interpreted.
  • Symptoms and examination: Persistent abdominal swelling, pelvic discomfort, or other concerning changes may warrant further assessment.

When an ovarian tumor is suspected, additional investigations may include pelvic ultrasound, other hormone measurements, and tumor markers such as inhibin B. These tests help evaluate the ovaries and identify whether there is a reason for further investigation.

Not every detectable AMH result requires imaging or extensive testing. The appropriate evaluation depends on the complete clinical picture rather than the AMH number alone.

When Should You Discuss an AMH Result With a Doctor?

Discuss an unexpected AMH result with a gynecologist or an appropriate specialist, particularly when the result is clearly elevated, remains measurable on repeat testing, or differs substantially from previous measurements.

Medical review is especially important when there is a previous history of granulosa cell tumors or other ovarian conditions. New or persistent pelvic pain, abdominal swelling, pressure, or bleeding after menopause should also be evaluated, regardless of the AMH result.

For women with a known ovarian tumor, the specialist will interpret AMH as part of the established follow-up plan rather than relying on an isolated blood test.

In most cases, the most useful approach is to understand why the test was performed and interpret the result alongside the person's age, medical history, examination, and other relevant investigations.

Frequently Asked Questions

Common questions about AMH levels, detectable results, and ovarian health after menopause.

Can AMH levels be zero after menopause?

Yes. AMH levels commonly fall below the detection limit of laboratory tests after menopause because ovarian follicle activity has declined. Some laboratories report these results as zero or undetectable. The exact result depends partly on the sensitivity of the testing method.

Is a high AMH level after menopause a sign of ovarian cancer?

Not necessarily. Certain granulosa cell tumors can produce AMH, but an elevated result alone cannot diagnose ovarian cancer. Laboratory differences and other clinical factors must also be considered. Further evaluation is appropriate when the result or medical history raises concern.

Can AMH levels predict when menopause will happen?

AMH levels decline as ovarian follicles decrease and may provide information about ovarian reserve during the reproductive years. However, a single AMH measurement cannot reliably predict the exact timing of menopause. It is also not recommended as a routine test to diagnose menopause in women older than 45 with typical menopausal symptoms.

Should AMH be tested routinely after menopause?

No. Routine AMH testing is generally unnecessary after natural menopause. It may be useful in specific circumstances, such as monitoring certain ovarian tumors when AMH was elevated at the time of diagnosis. Testing should be guided by a relevant medical reason rather than used as a general health screening test.

Citations

  1. MedlinePlus – Anti-Müllerian Hormone Test
  2. National Library of Medicine – Menopause, StatPearls
  3. European Society of Endocrinology – Clinical Practice Guideline for Evaluation and Management of Menopause and the Perimenopause
  4. Fertility and Sterility Reports – Potential Pitfalls of Reproductive Direct-to-Consumer Testing
  5. National Library of Medicine – Granulosa Theca Cell Tumors of the Ovary, StatPearls
  6. International Journal of Gynecology and Obstetrics – Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2025 Update
Share this article